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THE EMERGING ROLE OF MESENCHYMAL STROMAL CELLS AMONG 
THERAPEUTIC OPTIONS FOR CHRONIC OBSTRUCTIVE PULMONARY 
DISEASE 
 




 Chronic obstructive pulmonary disease (COPD) is the third leading cause of death 
worldwide. Smoking is the primary known risk factor in the development of COPD. 
Noxious particle or gas exposure to cells in the lungs leads to a chronic and sometimes 
irreversible state of airway inflammation, resulting in airflow limitation, hyper production 
of mucous, and destruction of distal lung tissue including gas exchange surfaces. COPD 
patients often develop dyspnea (difficult or labored breathing) and can become hospitalized 
during acute exacerbations. Current treatment options for COPD include exercise therapy, 
oxygen therapy, and multiple drugs with bronchodilation activity. These therapies aim to 
reduce dyspnea and exacerbation frequency. Steroid resistance in COPD patients has made 
treatment of underlying chronic inflammation difficult. Multiple targeted non-steroidal 
anti-inflammatory drugs (NSAIDs) are under investigation as potential therapeutic options. 
To this point, there is no approved treatment which adequately combats chronic 
inflammation in COPD. Mesenchymal stromal/stem cells (MSCs) have become 
increasingly of interest in recent years as a potential therapeutic option for multiple 
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different diseases in the body due to their demonstrated anti-inflammatory, 
immunomodulatory, tissue regenerative, and trophic signaling capacities. In the search for 
better ways to treat COPD, researchers have turned to MSC therapy as a potential solution. 
Preclinical studies demonstrated an ability of transplanted MSCs to ameliorate alveolar 
destruction and suppress inflammation in rodent models of COPD. Phase I clinical studies 
have identified safety, tolerability, and feasibility of MSC therapy in COPD, and 
preliminary findings suggest potential anti-inflammatory capacities which allow for 
improved lung function and quality of life. Many questions are still left unanswered in the 
study of MSC therapy in COPD, including the proper cell source and delivery route, and 
whether MSC-derived products might deliver equal or better results than transplanted cells. 
Currently, there is much optimism surrounding MSC therapy in COPD, as it has 
demonstrated a potential to relieve chronic inflammation through a multitude of signaling 
pathways as well as aid in regeneration of lung tissue. Further research is needed to uncover 
the optimal mechanism of MSC therapy in COPD and whether it will become a new 
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Chronic Obstructive Pulmonary Disease (COPD), a chronic inflammatory disease 
of the lungs, is currently the third leading cause of death worldwide.1 A 2015 meta-analysis 
of population-based studies around the world estimated global COPD prevalence to have 
risen from 10.7% to 11.7% from 1990 to 2010.2 Cigarette smoking has been well 
documented as a primary risk factor associated with the onset of COPD, and the expanding 
epidemic of smoking has undoubtedly played a role in the increased prevalence of the 
disease. That said, a minority of long-term smokers actually develop COPD, suggesting 
contributions of other risk factors.3 
Air pollution, genetics, childhood lung infections, asthma, and socioeconomic 
status have all been linked to likelihood of COPD development. Whether each of these 
plays a clear causative role in COPD development is not entirely agreed upon. Common 
comorbidities with COPD include cardiovascular disease, lung cancer, osteoporosis, 
skeletal muscle dysfunction, metabolic syndrome, depression, and anxiety.3 Advancements 
have been made in understanding the nature and origins of COPD, yet the scientific 
community remains in search of better ways to treat it. 
 
Pathogenesis and Diagnosis of COPD 
COPD is characterized by persistent airflow limitation and respiratory symptoms 
due to noxious particle or gas exposure. The development of chronic inflammation of the 
lungs leads to airway and/or alveolar abnormalities including narrowing of the small 
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airways and destruction of lung parenchyma. Inflammation can cause thickening of airway 
walls and goblet cell hyperplasia leading to hyper production of mucous which may 
partially or entirely occlude airways. Parenchyma destruction can detach alveoli from small 
airways and/or diminish elastic recoil. Disease progression differs among COPD patients, 
but the result can be a combination of conditions such as chronic bronchitis, refractory 
asthma, and emphysema.4 Emphysema is a rather general pathological term used to 
describe the destruction of the gas-exchange surface in the lung. Frequently encountered 
in COPD is a loss of airway mucociliary function, which in a healthy individual involves 
the sweeping of particles and dissolved gases up and out of the respiratory tract.3 Figure 1 
illustrates airway and alveolar disease pathology. 
 
Figure 1: Illustration of airway and alveolar pathologies in COPD. 
Taken from (Inacio, 2015)5 
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The most widely accepted diagnostic tool included in studies of COPD, proposed 
by the Global Institute for Chronic Obstructive Lung Disease (GOLD), is spirometry. The 
key metric is a measurement of forced expiratory volume in one second (FEV1)/forced vital 
capacity (FVC). Vital capacity describes the largest volume of air an individual can expel 
following the deepest possible breath. An FEV1/FVC value below 0.7 indicates COPD.1 
More simply explained, COPD patients are capable of expelling a smaller percentage of 
their vital capacity in a one second exhale than are healthy patients, leading to a lowered 
breathing capacity and in some cases hyperinflation of the lungs. Dyspnea (difficult or 
labored breathing) is very common, and oxygen reserves can be rapidly depleted with 
modest exercise or even just walking a short distance.6 Exacerbations of COPD, which 
vary in frequency and severity among patients, are a key focus of physicians and if 
uncontrolled can lead to complications requiring additional medical attention or even 
irreversible loss of lung function.4 For these reasons, patients with especially low 
FEV1/FVC values must be monitored closely. 
 
Chronic Inflammation and Lung Destruction 
 The hallmark COPD components of alveolar wall destruction, mucous 
hypersecretion, and decreased FEV1 occur secondarily to structural changes on the cellular 
level including airway wall inflammation, goblet cell metaplasia, and muscle hypertrophy. 
These cellular changes come about as result of a chain of inflammatory events. Noxious 
particle or gas exposure to epithelial cells, endothelial cells, and leukocytes in the lung can 
alter the expression of pattern recognition receptors (PRRs) on cell surfaces. This in turn 
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leads to excessive cytokine production, activating and recruiting inflammatory cells to the 
airway.7 
An accumulation of macrophages and T lymphocytes in the airway wall and 
neutrophils in the airway lumen causes a spike in protease production, including matrix 
metalloproteinases (MMPs) and neutrophilic elastases secreted from epithelial cells and 
neutrophils. MMPs and elastases under normal conditions contribute to the turnover of 
lung extracellular matrix (ECM) components collagen, gelatin, and elastin. When 
overproduced, these enzymes destroy lung tissue. Oxygen radicals released by activated 
macrophages and neutrophils can trigger oxidative stress. When the detoxification system 
becomes overwhelmed, oxygen radicals wreak havoc on cells, inflicting damage 
indiscriminately on cell components including mitochondria and DNA, and disrupting 
signaling pathways.7 Oxidative stress-induced mitochondrial dysfunction can further the 
inflammatory and tissue destructive processes in the lung.8 These changes are what make 
COPD fundamentally a chronic inflammatory disease, and signaling imbalances underly 






Figure 2. Cells and signaling causing structural changes in COPD. 
Taken from (Kato and Hanaoka, 2017)7 
 
While COPD may initially develop from inflammatory changes spurred by a 
reaction of lung cells to noxious particles or gas, it can enter a cycle of perpetuated 
deterioration even after the initial irritant is removed. Damage-associated molecular 
patterns (DAMPs) are released from an increasing number of dying cells in the lung, and 
this leads to increased cell apoptosis, suppressed removal of apoptotic cells by 
phagocytosis, and induction of hypoxia and oxidative stress. This all serves to prolong 
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inflammatory changes and maintain a diseased state even in the absence of the initial 
trigger.7 
  
Approved and Experimental Treatments for COPD 
There are a range of currently approved treatments for COPD. The various 
treatments target different aspects of the disease, and a variety of factors dictate which 
interventions are applicable to which patients. Some therapies have focused on expanding 
breathing capacity or oxygen intake to reduce dyspnea, while others focus on combatting 
underlying inflammation. The most rudimentary approach for smokers is to quit smoking, 
as it has been shown that cigarette smokers have a higher prevalence of respiratory 
symptoms and lung function abnormalities, a faster decline in FEV1, and a greater COPD 
mortality rate.9 While this is an important and productive step, COPD may not resolve of 
its own accord upon smoking cessation, as inflammatory changes of the lung can become 
irreversible.7 
Pulmonary rehabilitation is an intervention which involves tailoring exercise 
therapies for a patient along with promotion of behavioral changes, which together are 
designed to improve physical condition and enhance the odds of adherence to healthy 
lifestyle choices moving forward.1 A 2015 meta-analysis comparing COPD patients in a 
pulmonary rehabilitation intervention group with a group receiving usual care found 
significant improvement in dyspnea, fatigue, emotional function, and sense of control over 
one’s condition.10 Studies continue to examine exactly which components of pulmonary 
rehabilitation programs are essential and what methods are most effective. While not a 
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targeted therapy for underlying chronic inflammation and lung destruction, pulmonary 
rehabilitation is an accepted and widely administered component of integrated care for 
COPD.3 
Oxygen therapy is an additional approach to treatment which has been around for 
decades. In patients with severe hypoxemia, administration of oxygen via a concentrator 
has been shown to lower mortality at 3 years by as much as 21.5%.11 Oxygen therapy is 
frequently administered within a hospital during a COPD exacerbation, along with 
ventilatory support, but it is a cumbersome long-term option, although medical equipment 
has improved over time making this a viable option for more patients with advanced 
COPD.3 12 
For a long time, the pharmacologic treatment options were limited mainly to three 
categories. Antibiotics were used to treat COPD-associated infections, mucolytics to 
decrease sputum density with hopes of increasing clearance, and nonselective 
sympathomimetics for bronchodilation. Not only were these drugs limited in efficacy, but 
they also each came with a number of drawbacks.4 More recently, a variety of new drug 
therapies have become important additions to COPD treatment regimens. 
Bronchodilators are medications aimed at increasing FEV1, typically through 
relaxation of airway smooth muscle to widen airways. Bronchodilators include muscarinic 
acetylcholine receptor antagonists, beta-adrenergic receptor agonists, methylxanthines, and 
multiple novel classes currently in developmental and experimental stages. 
Bronchodilators have been shown to significantly increase both FEV1 and FVC in COPD 
patients, however improvements in dyspnea and exercise capacity vary and do not directly 
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mirror changes in FEV1.13 More importantly, they are designed to alter expiration capacity 
and prevent lung hyperinflation without any anti-inflammatory action. 
Inhaled corticosteroids (ICS), the primary treatment option in bronchial asthma, are 
frequently used in combination therapy with bronchodilators with the goal of suppressing 
inflammation in COPD patients. While anti-inflammatory properties of ICS have proven 
efficacious in treating bronchial asthma, chronic inflammation present in the lungs of 
COPD patients is different and somewhat less understood than that in bronchial asthma.14 
Outcomes of studies on ICS in treatment of COPD have varied, leading to no clear 
consensus on their efficacy. 
A 2012 meta-analysis of COPD patients found no reduction in rate of FEV1 decline 
in patients on long-term (greater than six months) ICS and no significant effect on 
mortality, with a slight reduction in exacerbation frequency and rate of decline of quality 
of life. The same study highlighted an increased risk of oropharyngeal candidiasis and 
hoarseness on long-term ICS.15 The reduced responsiveness to anti-inflammatory effects 
of corticosteroids in patients with COPD is a widely accepted phenomenon now. More 
research has built a better understanding of molecular mechanisms causing steroid 
resistance and helped identify novel therapeutic targets. 
More targeted nonsteroidal anti-inflammatory drugs (NSAIDs) such as 
phosphodiesterase-inhibitors, kinase inhibitors, and specific cytokines and chemokines 
have recently been of great interest to researchers hoping to circumvent steroid resistance 
in COPD and target the persistent nature of inflammation.16 Phosphodiesterase type 4 
(PDE4) hydrolyzes cyclic adenosine monophosphate (cAMP) in inflammatory cells, 
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regulating multiple cellular processes. PDE4 inhibitors effectively inhibit leukocyte 
activation, chemotaxis, and cytokine production, and have been shown to reduce airway 
inflammation, improve lung function, and reduce exacerbations in patients with more 
advanced COPD.17 18 PDE3 inhibitors, on the other hand, have proven effective 
bronchodilators through smooth muscle relaxation, and a PDE3 and PDE4 dual inhibitor, 
RPL554, is currently being studied for combined bronchodilation and anti-inflammatory 
function.19  
Multiple kinases regulate transcription factors for the production of cytokines, 
chemokines, and proteinases involved in airway inflammation in COPD. Inhibitors for 
kinases p38 MAPK, PI3K, JAK, and NF-kB are being studied as anti-inflammatory 
agents.16 Of these, only MAPK inhibitor has made it to clinical trials with COPD patients, 
showing improvement in lung function and dyspnea.20 This method is a promising 
approach to combatting chronic inflammation in COPD. 
Cytokines, including TNF-𝛼, IL-1𝛽, IL-6, IL-17, and GM-CSF, as well as the 
chemokine IL-8, play important roles in mounting inflammatory responses. As such, 
researchers are examining approaches to disrupt these pathways using antibodies, receptor 
antagonists, and intracellular signaling inhibitors. Studies have not yet yielded results 
proving efficacy of these therapies, but research continues.16 
Lastly, retinoids have emerged as a potential therapeutic option specifically for 
emphysema patients. It is understood that retinoic acid plays an essential role in generation 
of alveoli during development, and multiple animal models have shown an ability of 
retinoic acid to aid in regeneration of alveoli in vivo. One study found that all-trans retinoic 
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acid (ATRA) was able to reverse elastase-induced pulmonary emphysema changes in 
rats.21 Unfortunately, animal models are not perfect representations of the human 
emphysema condition, and these results have failed to be replicated in human emphysema 
patients, with lung function and quality of life metrics making no significant improvements 
on ATRA.22 
 
Therapeutic Approach Target of Therapy Clinical Use 




Part of integrated patient 
management 
Oxygen therapy Reduce hypoxemia Hospital treatment during 
exacerbation 
Bronchodilators  
o muscarinic Acetylcholine 
receptor antagonists 
o beta-adrenergic receptor 
agonists 
o methylxanthines 
Increase expiratory flow 
















*Therapies in clinical trial phase 
 
Table 1. Current COPD therapeutic options. 
Adapted from (Global Initiative for Chronic Obstructive Lung Disease. Global Strategy 
for the Diagnosis, Management, and Prevention of Chronic Obstructive Pulmonary 
Disease. 2021 Report.)23 
 
 
Table 1 summarizes the current therapeutic options for treating COPD, along with 
the target of each therapy and the manner in which each is used clinically. While individual 
or combination therapies using the aforementioned approaches have had success at 
	
11 
reducing the frequency of COPD exacerbations or limiting them when they occur, 
reversing the disease’s course has been a more elusive goal. The most well-established 
therapies largely focus on remedying symptoms such as dyspnea, and while reducing the 
recruitment/expansion of cells involved in the inflammatory response is the primary focus 
of some new experimental NSAID therapies, there is not yet an effective treatment to 
suppress airway inflammation and prevent or reverse disease progression.  
Considering the disease’s pathogenesis, whereby chronic inflammation leads to 
constant destruction of lung tissue and the gradual deterioration of lung function, a therapy 
is needed which can suppress inflammation enough to allow the lung to rebuild, and if 
possible aid in the process of regeneration. 
 
Mesenchymal Stromal Cells 
Resident stem cells in various organs are key for standard cell turnover that occurs 
during homeostasis, due to their ability to differentiate into multiple lineages. Different 
types of stem cells in the lung are responsible for maintenance of different pools of 
terminally differentiated cells, and during times of stress to the lung environment they play 
a role in modulating the inflammatory response.24 However, chronic inflammation of the 
lung may also have a damaging effect on the pools of stem cells available. It has been 
shown that basal stem cells isolated from COPD patients have a reduced capability of 




The field of stem cell research has been rapidly expanding in its relevance to 
therapy for many different disease states in different organ systems. One specific cell type 
that has gained much traction over the last two decades is the mesenchymal stem cell, 
known more or less synonymously as the mesenchymal stromal cell (MSC). There are 
many reasons for the interest in MSCs as a potential agent of cell therapy, including a body 
of research identifying tissue-regenerative, immunomodulatory, anti-inflammatory, and 
trophic signaling capacities. Secondarily, the ease of isolation from bone marrow, adipose 
tissue, and umbilical cord, and the remarkably low immunogenicity of MSCs further make 
the case for their therapeutic potential.26 
MSCs are multipotent stem cells with the capacity to differentiate into a variety of 
terminally differentiated mesodermal cell types including bone, fat, and cartilage. First 
discovered in bone marrow in 1968, MSCs were initially studied mostly for their role in 
aiding hematopoiesis and in forming bone and cartilage. As such, the first clinical 
application of MSC therapy involving direct infusion into humans was performed by 
hematologists in 1995, the first step in illuminating the safety of this practice.26 In the years 
since the discovery and first clinical use of MSCs, much more has been learned about them. 
Importantly, it has been observed that isolated MSCs constitutively express low levels of 
human leukocyte antigen (HLA) class I but do not express HLA class II or costimulatory 
molecules CD40, CD80, and CD86. Expression of the latter four molecules are essential 
for T-cell immune response activation, and MSCs’ lack thereof permits allogenic 
administration without HLA matching.27 
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While the initial thought was that, as a multipotent stem cell, MSCs would primarily 
lend therapeutic benefits by aiding in fabrication of replacement tissues, research has 
shifted in the direction of harnessing their trophic signaling properties to battle disease in 
a number of different ways. Diseases which have been investigated for the use of MSC 
therapy include graft-versus-host-disease, multiple sclerosis, diabetes, tendonitis, 
osteoarthritis, rheumatoid arthritis, stroke, acute myocardial infarction, and asthma.28 Table 
2 lists the various bioactive factors secreted by MSCs and the many functions of these 
signaling molecules throughout the body.  
 
 
Table 2: Bioactive factors secreted by MSCs. 
Taken from (Mohammadipoor et al., 2018)29 
 
 
Of great interest to those investigating MSCs as a therapeutic option in 
inflammatory diseases are the immunomodulatory capacities of the cells. Table 3 
summarizes signaling processes between MSCs and different immune cells. Studies have 
identified capacities of MSCs to modulate immune and inflammatory responses through 
both paracrine and contact-dependent signaling to T cells, B cells, dendritic cells (DCs), 
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macrophages, natural killer (NK) cells, neutrophils, and mast cells. This means that MSCs 
can have multiple effects on both the innate and adaptive immune responses, rather than 
one single pathway. 
 
Target Cell Signal/Mechanism MSC Function 
T Cell TGF-𝛽, HGF, IDO, NO, PGE2, HLA-
G5, TSG6, IL-10, EVs 
Cell-cell contact: Fas/FasL signaling 
 
CXCR3 ligands, CCR5 ligands, ICAM-
1, VCAM-1 
 
Suppressing T cell differentiation, 
proliferation, activation, and survival 
 
 
Promoting T cell recruitment 
B Cell CCL2, IL-IRa, IDO, PGE2, 
complement C3, EVs 
Cell-cell contact: PD-1, PD-L1 
 
VEGF 
Suppressing B cell differentiation, 
proliferation, activation, and chemotaxis; 
Breg induction 
 
Promoting B cell differentiation, 
proliferation, and activation 
 
DC IL-6, IL-10, M-CSF, PGE2, EVs 
Cell-cell contact: notch pathway 
activation 
 
Suppressing DC differentiation, activation, 
endocytosis, migration, and maturation 
Macrophage PGE2, IDO, IL-IRa, IL-10, TSG-6, 
TGF-𝛽, exosomes 
Suppressing M1 while inducing M2 
polarization 
NK Cell IDO, PGE2, HLA5, EVs 
Cell-cell contact: CD73, TLR4 
 
CCL2 
Suppressing NK cell proliferation, 
migration, and activation 
Promoting NK cell progenitor proliferation 
and NK activation 
 




IL-6, IL-8, MIF, IFN-𝛽, GM-CSF 
Suppressing neutrophil activation, 
recruitment, neutrophil extracellular trap 
formation, and protease secretion 
 
Promoting neutrophil survival and 
recruitment 
 
Mast Cell PGE2, TGF-𝛽1 Suppressing mast cell degranulation, 




Table 3. MSC regulation of different immune cells. 





MSCs fit logically as a potential COPD therapy due to their known ability to 
simultaneously target multiple pathological processes. MSCs exist primarily in bone 
marrow but are also found as resident cells in numerous other tissues, including lung. As 
resident lung cells, MSCs modulate immune responses, but also carry out vital tissue repair 
and regeneration and activate other cells to do the same.31 Numerous studies have 
approached the question of how MSC treatment impacts the inflammatory response and 
the regeneration process of lung tissue that has been damaged by COPD, with the hope of 
designing a viable treatment option in which MSCs may be transplanted into COPD 
patients to reverse the course of the disease. 
 
Specific Aims 
With a burgeoning field of research focused on testing the safety and efficacy of 
MSCs as a novel therapeutic approach to treating COPD, there exist past review articles 
which combine study findings at different points in time. The aims of this manuscript are 
four-fold. First, provide a view of the progress which has been made in understanding the 
mechanisms which link MSC therapy to COPD. Second, examine progress in developing 
and testing MSC therapy for COPD. Third, describe the benefits and drawbacks of current 
approaches in the context of other alternative approaches to MSC therapy. And fourth, 
consider the place for MSC therapy among alternative approaches to COPD treatment, both 





 Over the past decade, with MSC therapy yielding encouraging results in a diverse 
group of diseases, and immunomodulatory and regenerative capacities of MSCs becoming 
clearer, researchers have been making headway directing MSC therapy towards COPD. 
 
MSC Characteristics and Relevance to COPD 
 MSCs have demonstrated tremendous regenerative, immunomodulatory, anti-
inflammatory, and trophic paracrine capabilities. Our understanding of these mechanisms 
has grown alongside a constantly expanding knowledge of the underlying mechanisms 
driving COPD changes in the lung. Studies have examined the many actions of MSCs as 
they relate to lung diseases, as well as the impact of COPD on native lung mesenchyme, 
expanding the ability to develop MSC therapies to be tested in COPD. 
 COPD alters lung morphology and function, but it begins with changes at the 
cellular level impacting different cell types in the lung. Understanding how MSCs are 
altered in COPD is critical. Multiple publications have described the reduced capacity for 
tissue repair in lung fibroblasts during COPD.32 33 Building on these works, a study showed 
that fibroblasts and MSCs share many characteristics and markers in the lung, and both 
cells have diminished migration and differentiation abilities when exposed to chronic 
cigarette smoke.34 Bone marrow-derived MSCs (BM-MSCs) isolated from COPD patients 
evaluated for expression of chemokines and chemokine receptors showed decreased 
CXCR4 mRNA. This specific chemokine receptor plays an important role in MSC 
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migration, providing an explanation for previously observed reduction in MSC migratory 
capacity in COPD patients.35 
 A study in guinea pigs provided a more holistic view of the impact of cigarette 
smoke on properties of BM-MSCs. While a greater number of BM-MSCs infiltrated the 
lungs in animals exposed to cigarette smoke, the BM-MSCs from those same cigarette 
smoke exposed animals developed a reduced engrafting ability when tested on donor lungs. 
In vitro testing of the cells in this study corroborated earlier findings, with cigarette smoke-
exposed BM-MSCs having reduced proliferation and migration rates.36 
 These studies highlight alterations in the MSCs of COPD patients and relevant 
animal models, including their generic stem cell properties such as migration and 
proliferation as well as tissue regeneration. The impact on immunomodulatory capacities 
of MSCs in COPD patients is perhaps more critical, given the pathogenesis of the disease. 
A 2019 study compared immunomodulatory capacities of lung resident MSCs (LR-MSCs) 
isolated from four different patient populations: nonsmokers, former smokers, COPD 
former smokers, and COPD current smokers. When tested in vitro, the first three groups of 
cells showed equal capabilities of reducing proliferation of CD8+ T lymphocytes, however 
the LR-MSCs from COPD current smokers had a significantly reduced capability or 
reducing CD8+ T lymphocyte proliferation.37 
 It is well documented that cigarette smoke and other irritants can be harmful to 
many cell types in the lungs, as this can be what spurs COPD development and progression 
in many patients. As such, it is unsurprising to discover that MSCs are adversely affected 
by smoking and during COPD development. The confirmation of specific ways in which 
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MSCs are harmed in COPD patients highlights the potential benefit of MSC 
transplantation, as does the body of research surrounding MSC therapy in other 
inflammatory diseases. Understanding the capacity of non-COPD MSCs to combat chronic 
inflammation, and the mechanics of this process, is important step in considering their use 
as a therapy. MSCs cultured in vitro using an airway epithelial wound closure assay 
increased the rate and extent of wound closure when stimulated with pro-inflammatory 
cytokines TNH-𝛼 and IL-1𝛽. This was discovered to be largely the result of increased MSC 
production of epidermal growth factor receptor (EGFR), a ligand which was previously 
suggested as one primary mechanism by which MSCs reduce inflammation and promote 
alveolar structural repair.38 
 So, with evidence of MSCs responding to inflammatory signals by enhancing 
production of ligands which simultaneously act to suppress said inflammation and promote 
lung tissue repair, a clear connection is drawn between how MSCs are impaired during 
COPD development, and how they respond to inflammatory signals when healthy. 
 
Alveolar Regeneration 
 Animal models of chronic human lung conditions are absolutely necessary but 
inherently limited. As referenced in section 1.3, multiple mouse and rat studies showed 
great promise for ATRA-induced alveolar regeneration in emphysema. Elastase and 
cigarette smoke were used to induce a model of emphysema in the animals, and the 
treatment appeared effective at reversing alveolar damage.21 Once this medication was 
moved to clinical trials on actual emphysema patients, the clear improvements shown in 
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rodents did not materialize.22 Animal models are still a critical and required step in creating 
an understanding of a therapy’s safety and efficacy in vivo, and a lack of proven efficacy 
at this stage garners questions about any potential benefit at all, but efficacy of any 
treatment will not be confirmed until demonstrated through clinical trials. 
15 years ago, researchers began testing MSCs on rodent models of chronic lung 
disease, even without todays more comprehensive understanding of MSC signaling 
capabilities. The research initially focused specifically on emphysema, due to the known 
ability of MSCs to differentiate into alveolar epithelial cells. Emphysema is one of multiple 
possible pathologic components of COPD, in which gas exchange surfaces in the lung are 
destroyed. In the first study of its kind, 28 days after MSC intravenous injection into rats 
with irradiation and papain induced pulmonary emphysema, the emphysema was 
significantly ameliorated in the experimental group when compared to a control group 
which received no MSC injection. MSCs were harvested from male donors and underwent 
Y chromosome fluorescent in situ hybridization (FISH) for tracking purposes prior to 
injection into female emphysema recipients. This study reported MSC engraftment in 
recipient lungs followed by differentiation to type II alveolar cells. Additionally, as 
compared to emphysema rats receiving vehicle control, those which received MSC 
injection showed a reduction in in apoptosis of distal lung cells as demonstrated by 
decreased TUNEL+ stained cells and decreased expression of the apoptosis associated 




The results of this first study have been replicated by multiple different groups, 
with varying animal models and study designs. Some study designs opted for different 
MSC sources and also different routes of MSC delivery. Techniques used to model lung 
destruction and inflammation seen in COPD have also varied and include papain 
administration, lung irradiation, elastase administration, lipopolysaccharide (LPS) 
administration, and viral vector or bacteria administration. Cigarette smoke (CS) exposure 
is commonly referenced as a model with potentially more clinical relevance for COPD in 
humans. The studies using these models are collectively quite valuable. 
A 2011 study showed BM-MSCs administered via retrobulbar injection to rats after 
6 months of cigarette smoke exposure alleviated emphysema, pulmonary hypertension, and 
pulmonary vascular remodeling. Compared to controls, BM-MSCs restored alveolar 
architecture, reduced mean linear intercept (MLI) to normal levels, and reduced right 
ventricular systolic pressure (RVSP) to normal levels.40 MLI is a common metric used in 
histological analysis of distal lung, measuring the average distance between sections of 
alveolar septum. In emphysema lung tissue, this value is often increased due to destructed 
and overinflated alveoli. 
In another study, rat MSCs were used to treat rats with CS-induced emphysema and 
pulmonary dysfunction. In the MSC treatment group, ECM remodeling enzymes MMP9 
and MMP12 were decreased and an upregulation in VEGF, VEGF receptors, and TGF𝛽-1 
played a part in reducing cell apoptosis.41 Finally, in another CS-induced rat emphysema 
study, amniotic fluid-derived MSCs infused into rat lungs showed an ability to differentiate 
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into alveolar type II cells, decrease type II cell apoptosis, increase type II cell proteins SP-
A and SP-C, and alleviate lung injury.42 
In mice with elastase-induced pulmonary emphysema, alveolar pathology was 
improved after intravenous injection of Wharton’s Jelly-derived (WJ) MSCs, with 
histological examination revealing a significant reduction in MLI as compared to the 
control group.43 In a study using a different model, the non-viral vector DDMC was used 
to induce emphysema in mice, and groups receiving 3 different doses of MSC infusion 
each developed less damaged lung tissue than in control animals.44 
 
Cell Source Route Emphysema Model Outcomes Ref. 
BM IV Rat: Irradiation & Papain ↓ emphysema 
↓ apoptosis 
type II differentiation 
45 




BM IT Rat: CS ↓ MMPs 
↑ VEGF, VEGFr, TGF-𝛽1 
↓ apoptosis 
41 
AF IT Rat: CS ↓ apoptosis 
Type II differentiation 
↑ SP-A, SP-C 
42 
WJ IV Mouse: elastase Improved alveolar architecture 
↓ MLI 
43 
BM IT Mouse: DDMC vector ↓ damaged lung tissue 44 
BM – bone marrow. AF – amniotic fluid. WJ – Wharton’s Jelly. IV – intravenous. IT – intratracheal. CS – 
cigarette smoke. MLI – mean linear intercept. RVSP – right ventricular systolic pressure. MMP – matrix 
metalloproteinase. SP-A – surfactant protein A. SP-C – surfactant protein C. 
 




Table 4 summarizes MSC-mediate benefits of alveolar regeneration in models of 
emphysema. These studies provided a foundation of evidence showing the ability of 
transplanted MSCs to relieve alveolar destruction in animal models of emphysema. 
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Alveolar regeneration is a critical component in the ideal therapy for a patient suffering 
from emphysema, and these studies highlight the tissue regenerative potential of MSCs in 
the lung. Pulmonary emphysema, however, is often a result of chronic airway inflammation 
in a COPD patient. If underlying signaling imbalances are not addressed, it is reasonable 
to anticipate limited enduring benefit from alveolar regeneration alone. 
 
Amelioration of Chronic Inflammation 
More animal models have been tested to examine a broader range of effects that 
MSCs can have in COPD. Important considerations beyond alveolar and general lung 
tissue destruction described above are impacts on chronic inflammation and oxidative 
stress caused by an increase in reactive oxygen species (ROS). Combatting these changes 
in the lung in addition to reversing lung destruction is critical to developing a viable 
treatment for COPD. 
One of the previously mentioned studies, in which rat MSCs were administered to 
rats which had developed CS-induced emphysema and pulmonary dysfunction, showed 
distinct anti-inflammatory actions of transplanted MSCs. In the treatment group there was 
a reduction of inflammatory mediators TNF-𝛼, IL-1𝛽, MCP-1, and IL-6.41 In another 
model using LPS infusion to induce COPD in mice, MSCs delivered intravenously 
inhibited the inflammatory IL-6 response and reduced neutrophil numbers in 




Many more studies have built on these findings that transplanted MSCs can have 
anti-inflammatory effects in rodent models of COPD and examined closer the mechanisms 
by which this occurs. A study of CS-induced COPD mice found that intratracheal MSC 
infusion led to an overall reduction in emphysema and airway inflammation pathology, as 
well as downregulation of inflammatory mediators cyclooxygenase-2 (COX-2) and 
prostaglandin-2 (PGE-2), as demonstrated by immunohistochemistry, western blot, real-
time PCR, and an enzyme immunoassay. In vitro experiments suggested this 
downregulation occurs by MSC signaling to macrophages leading to inhibition of two 
kinases, p38 MAPK and ERK. In addition, this study also found MSC-induced reductions 
in inflammatory mediator IL-6 and total macrophage number, but an increase in IL-10.47 
Interestingly, IL-10 is one ligand responsible for suppressing inflammatory cytokine 
production. 
Three more studies corroborated and added to these findings. Intravenous 
administration of BM-MSCs to CS-induced COPD mice decreased inflammatory cell 
count in BALF, decreased apoptosis in the alveolar wall while relieving emphysema 
changes, and also increased the number of bronchoalveolar stem cells (BASCs).48 In mice 
with elastase-induced COPD, intravenous injection of MSCs had anti-inflammatory, anti-
fibrotic, and anti-apoptosis effects, which were linked to an increased production of 
hepatocyte growth factory (HGF) by MSCs. This was determined after HGF-knockdown 
MSCs failed to produce the same significant levels of benefit as a treatment.49 Lastly, 
another study used a combination of CS exposure and Haemophilus Parainfluenza (HPi) 
bacteria administration to develop a mouse model of COPD exacerbation. It was found that 
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intravenous administration of BM-MSCs reduced leukocyte infiltration in the lungs, 
reduced multiple inflammatory mediators, and increased expression of IL-10, in addition 
to reducing alveolar wall thickening, MLI, alveolar hemorrhage, and alveolar congestion. 
This study identifies both anti-inflammatory and anti-bacterial effects of MSC-
administration on lung injury.50 
In a 2016 study, a gene profile was generated for CS-induced COPD mice to 
examine changes upon intravenous administration of human cord blood-derived MSCs 
(hCB-MSCs). In the gene profile of the treatment group, genes associated with an immune 
response were upregulated, a contrast with results of other studies. The authors attributed 
this to a host reaction. However, the treatment group also showed upregulation of a serine 
protease inhibitor, oxygen transport genes, and the antioxidant genes Hbb and Hba.51 In 
addition to inflammation and lung destruction addressed by previous studies, oxidative 
stress is a critical component of COPD. With the system to detoxify reactive oxygen 
species (ROSs) impaired, ROSs can cause damage to virtually every part of the cell. A 
capacity to fight against oxidative stress by increasing oxygen transport and antioxidation, 
as suggested by the above study, would expand the potential efficacy of MSC treatment in 
COPD. 
Building on that study, another in 2018 exposed airway smooth muscle cells to 
cigarette smoke extract (CSE), which led to oxidative stress-induced mitochondrial 
dysfunction, a condition which can contribute to inflammation and remodeling in COPD. 
Coculture of these cells with induced pluripotent stem cell-derived MSCs (iPSC-MSCs) 
reduced cell apoptosis and production of reactive oxygen species (ROS), and also allowed 
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for mitochondrial transfer from MSC to airway smooth muscle cells. With the same 
endpoints in mind, this group exposed mice to ozone (3 ppm air) to induce COPD, then 
injected iPSC-MSCs intravenously. As with past experiments, airway inflammation and 
immune cell recruitment decreased, but additionally, as was seen in vitro, mitochondrial 
ROS were reduced. However, these benefits were only seen in a preventative manner when 
MSCs were given prior to ozone exposure, and did not deliver similar results as a treatment 
post-exposure.8 
 
Cell Source Route COPD Model Outcomes Key Factors Ref. 
BM IT Rat: CS Anti-inflammatory ↓TNF-𝛼, IL-1𝛽, MCP-1, IL-
6 
41 
BM IV Rat: CS Anti-inflammatory 
↓ neutrophils 
↓ IL-6 46 
BM IT Mouse: CS Anti-inflammatory 
↓ emphysema 
↓ COX-2, PGE-2 
 
52 





BM (human) IV Mouse: Elastase Anti-inflammatory 
↓ fibrosis 
↓ apoptosis 
↑ HGF 49 










CB (human) IV Mouse: CS ↑ immune response 
(host reaction) 
↑ oxygen transport 
↑ antioxidation 
↑ serine protease inhibitor 51 
iPSC IV Mouse: ozone Anti-inflammatory 
↓ immune cells 
(only preventative) 
 8 
BM – bone marrow. CB – cord blood. iPSC – induced pluripotent stem cell. IV – intravenous. IT – 
intratracheal. CS – cigarette smoke. HPi – Haemophilus Parainfluenza. 
 
Table 5: Summary of MSC-mediated anti-inflammatory and antioxidation benefits 





In sum, these many preclinical studies have indicated an ability of transplanted 
MSCs to carry out critical functions in the treatment of COPD. These include relieving 
lung destruction, regenerating alveoli, downregulating inflammatory mediators, decreasing 
inflammatory cell recruitment, and relieving oxidative stress. A 2016 meta-analysis 
examined preclinical studies of MSC administration in COPD. This study indicated that 
MSC treatment was significantly in favor of attenuating acute lung injury, stimulating lung 
tissue regeneration, and improving lung function. It also credits these findings to the ability 
of MSC treatment to significantly reduce airway inflammation and stimulate synthesis of 
cytokines involved in repairing lung tissue.53 
 
Phase I Clinical Trials 
 A body of work, including in vitro studies of MSCs and preclinical studies using 
animal models of COPD, has provided evidence to support MSC therapy as a potential 
COPD treatment in humans. Known immunomodulatory, anti-inflammatory, tissue 
regenerative, and trophic paracrine properties of MSCs have been shown to offer benefits 
in treating models of COPD. Clinical trials of MSC therapy in COPD have now been under 
way for about a decade. The primary goal of phase I clinical studies is to test safety of a 
given therapy, although more recent studies have begun to examine efficacy as well. In the 
case of MSC transplantation, past clinical studies studying MSC therapy for a range of 
diseases demonstrated that this practice is safe in a number of different recipient tissues.28 
At a minimum each Phase I study records a number of safety metrics. These include 
all potential MSC administration-related toxicities, serious adverse events, and deaths. 
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Number of adverse events, frequency and/or severity of COPD exacerbations, or worsening 
of disease have been examined. Efficacy endpoints have varied more widely than safety 
endpoints. Pulmonary function tests are common and can include spirometry 
measurements such as FEV1 and FEV1/FVC. The 6-minute walk test is a measure of 
exercise performance.54 Also common are metrics indicating quality of life and a patient’s 
self-assessment of disease. BODE (Body mass index, airway Obstruction, Dyspnea, 
Exercise index) functions as a predictor of mortality, hospitalization, an exacerbation 
frequency and severity. MMRC (modified medical research council) quantifies disability 
attributable to dyspnea. SGRQ (St. George’s Respiratory Questionnaire) is a standardized 
set of self-reported measures for assessment of impaired health and perceived well-being.55 
Finally, the CCQ (Clinical COPD Questionnaire) is used to assess self-assess symptoms, 
pulmonary function, and the mental component of disease.56 
Circulating C-reactive protein (CRP) is used as a COPD severity indicator, as it has 
been found to be a strong independent predictor of exacerbation, hospitalization, and 
mortality in COPD patients.57 The makeup and quantity of certain cytokines and cell types 
in circulation is also used as a predictor of treatment efficacy. In studies where lung tissue 
was isolated during lung volume reduction surgery, tissue can be further analyzed both 
histologically and for gene expression levels. Together, the varying studies with different 
designs and endpoints have provided the most valuable understanding of where MSC 
treatment for COPD currently stands. 
In 2013, a phase I double-blinded, randomized, placebo-controlled clinical study 
was published in which 62 COPD patients were enrolled. Each patient received non-HLA-
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matched allogenic MSCs or a vehicle control intravenously in 4 monthly infusions, with 
100×106 cells per infusion. Patients were then followed for 2 years. This study found no 
infusion-related toxicities, no deaths, and no serious adverse events related to MSC 
administration. Additionally, between the two groups there was not a significant difference 
in the number of adverse events, worsening of disease or the frequency of COPD 
exacerbations. Pulmonary function tests and quality of life were not significantly different 
between the two groups. Early on after MSC infusion, a group of patients with elevated 
CRP at the beginning of the study saw a decrease in circulating CRP, indicating a link 
between MSC administration and COPD amelioration.27 This study primarily aimed at 
evaluating safety of systemic MSC administration in moderate to severe COPD patients, 
and succeeded at doing so. 
A phase I clinical trial in 2016 focused on systemic administration of MSCs to 
patients with severe emphysema. This study, and most others to this point, was even 
smaller in size than the one described above. 10 patients who were requiring multiple lung 
volume reduction surgeries (LVRSs) as surgical treatment for severe emphysema were 
enrolled in this study, and by the study’s end 3 of the 10 were excluded as they were not 
able to complete all components. Patients received the first LVRS, at which point bone 
marrow was aspirated and MSCs were isolated and expanded in vitro. Next, the patients 
received 2 separate MSC intravenous infusions. 3 weeks after the second infusion, the 
second LVRS was performed, and the lung tissue removed was analyzed for multiple 




This study found no adverse events related to MSC infusion, and no fibrotic 
response was seen histologically in the tissue. There was a 3-fold increase in CD31 
expression in the isolated tissue at the second timepoint. This indicated a responsiveness 
of microvascular endothelial cells in severely damaged areas of the emphysematous lungs. 
Additionally, this study provided evidence that systemic MSC administration to severe 
emphysema patients is a safe practice.58 
Another study took a different approach of combining MSC administration with 
endobronchial valve (EBV) insertion in patients with pulmonary emphysema. EBVs are 
put in place in order to reduce air trapping in COPD lungs. However, the placement of the 
valve frequently causes local inflammation and as a result can sometimes worsen clinical 
status. The hypothesis of this phase I clinical trial was that intrabronchial MSC 
administration would reduce this local inflammation. 2 groups of 5 patients were enrolled 
in this prospective, patient-blinded, randomized, placebo-controlled study. BM-MSCs 
were harvested from a single healthy donor and expanded. In the treatment group, 100×106 
MSCs were infused into each visualized subsegmental airway division of a target lobe 
immediately prior to the placement of an EBV in the given location. In the placebo group, 
the same technique was used with administration of saline solution not containing any cells. 
Patients were then evaluated up to 90 days after the procedure.55 
In the combined MSC administration and EBV insertion study, there was no acute 
administration-related toxicity, no serious adverse events, and no death. There was also no 
significant difference in the number of adverse events, exacerbation frequency, or disease 
worsening. Blood tests, lung function, and radiological outcomes did not differ 
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significantly between the two groups. 3 different quality of life indicators, BODE, MMRC, 
and SGRQ, each improved significantly with MSC administration. And lastly, circulating 
CRP was discovered to decrease significantly in the MSC treatment group. While EBV is 
only an appropriate intervention in certain COPD patients with advanced pulmonary 
emphysema, this study demonstrated safety of MSC administration to COPD and 
emphysema patients through a direct intrabronchial route rather than systemic. It 
additionally identified the possibility of quality of life improvements in COPD patients 
receiving MSC infusion immediately prior to EBV placement.55  
In 2018, a group carried out a study which examined both systemic infusion and 
inhalation routes of stem cell delivery in COPD patients. 30 patients with COPD were 
enrolled, and each patient first received granulocyte colony-stimulating factor to mobilize 
stem cells in the bone marrow, then bone marrow was aspirated. In this study, rather than 
expand a purified population of MSCs, the authors chose to separate a layer of mononuclear 
cells which included a population of mobilized stem cells. The 30 patients were then 
separated into 3 groups of 10. All groups received medication based on GOLD 
recommendations, which included a long-acting 𝛽2 agonist and inhaled corticosteroids. 
The control group received only this medication, while the second group was given 
systemic stem cell infusion and the third group inhaled stem cells via a nebulizer. Both 
stem cell treatment groups were found to have increased pulmonary function in mild to 
moderate COPD 1 month later. Both treatment groups additionally showed improved 
quality of life using the CCQ scores as a metric.56 
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In 2018, phase I clinical studies of MSC therapy in COPD shifted focus slightly to 
capture immunomodulatory impacts of treatment more clearly. A group enrolled 9 mild to 
very severe stable COPD patients. Each patient was given BM-MSCs, harvested from their 
own bone marrow and expanded in vitro, in 2 intravenous infusions. Each infusion had 2 
x 106 cells per kg, and the cells were labeled with indium-111 for tracking purposes. 
Endpoints for each patient were analyzed in comparison to pre-infusion metrics. The study 
saw no adverse side effects of MSC administration, with treatment well-tolerated by all 
participants. Hospitalizations from acute exacerbation decreased from 11 the year before 
treatment to 6 the year after. No change to lung function was seen by spirometry testing. 
Indium-111 was detectable on CT scans within 30 minutes and up to 7 days in the lungs, 
and also appeared in liver, spleen, and bone marrow. It was found that MSCs were retained 
in lung vasculature of mild COPD patients longer than in severe COPD patients. A 
significant reduction in F2-isoprostanes at 7 days indicated a reduction in oxidative stress. 
In contrast with previous studies, circulating CRP was seen to increase at 2 days.59 
A number of inflammatory mediators remained undetectable both before and after 
MSC infusion in this study, but some which were detectable did change in level during the 
course of the study. CD163 was reduced 1-7 days after infusion. CD163 is involved in 
macrophage activation and often viewed as a correlate for disease severity. IL-6, a major 
COPD mediator which stimulates MMPs and the T cell response, was also seen to decrease. 
There was an increase in sTNFR1, an anti-inflammatory mediator which binds and 
sequesters the inflammatory cytokine TNF-𝛼.59 
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The makeup of circulating cells related to the inflammatory response also changed 
following MSC administration in this study. Circulating regulatory T lymphocytes (Tregs), 
central to resolution of inflammation and typically reduced in COPD, increased with 
MSCs. Also observed was a shift towards plasmacytoid dendritic cells (pDCs) from 
myeloid DCs (mDCs). mDCs are a major source of T-cell stimuli and inflammatory 
cytokines, and an increase in mDC:pDC ratio is associated with greater emphysematous 
changes in COPD. This study observed the mDC:pDC ratio moving in the other direction. 
There was also an increase in CD14+ monocytes at day 2 with reduced co-stimulatory 
molecules and reduced pro-inflammatory receptors, suggesting that monocytes in the lung 
were adopting a more immunoregulatory phenotype.59 
In 2020, a group enrolled 5 COPD patients to receive 4 intravenous doses of 
umbilical cord tissue-derived MSCs at 2 weeks increments. The 3 primary endpoints of 
respiratory function — (FEV1/FVC), quality of life (SGRQ score), and exercise capacity 
(6-minute walking test) — each improved significantly from before MSC treatment.60 
Finally, a 2020 study enrolled 20 COPD patients who received 1.5×106 MSCs by systemic 
administration. Safety and efficacy tests followed at 1, 3, and 6 months. No infusion related 
toxicities, serious adverse reactions, or deaths were observed. MMRC scores were reduced, 
indicating improved quality of life, and COPD assessment test and number of 
exacerbations were also reduced. There were nonsignificant improvements in circulating 
CRP, 6-minute walking test, and FEV1. Conclusions of these final two studies were that 
MSC systemic administration to COPD patients is safe and offers a potential benefit for 
quality of life and breathing capacity. 
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Cell Source Route No. Patients Outcomes Ref. 
BM IV 62 Safe, tolerable, feasible 
↓ CRP 
27 
BM IV 10 Safe, tolerable, feasible 
Microvascular response (↑ CD31) 
58 
BM IB – with 
EBV 
placement 
10 Safe, tolerable, feasible 




BM IV or inhaled 30 Safe, tolerable, feasible 
Improved pulmonary function 
Improved quality of life indicators (CCQ) 
56 
BM IV 9 Safe, tolerable, feasible 
Decreased hospitalization 
Reduced oxidative stress (↓F2-isoprostanes) 
↑ CRP 
Anti-inflammatory changes: 
o ↓ CD163 (macrophage activator) 
o ↓ IL-6 (inflammatory cytokine) 
o ↑ sTNFR1 (anti-inflammatory cytokine) 
o ↑ Tregs 
o ↓ mDC:pDC 
o ↑ CD14+ monocytes 
59 
UCT IV 5 Safe, tolerable, feasible 
Improved pulmonary function (↑ FEV1/FVC) 
Improved exercise capacity (6MWT) 
Improved quality of life (SGRQ) 
60 
UCT IV 20 Safe, tolerable, feasible 
Reduced exacerbations 
Improved COPD assessment test 
Improved quality of life (MMRC) 
54 
BM – bone marrow. UCT – umbilical cord tissue. IV – intravenous. IB – intrabronchial. CRP – C-reactive 
protein. BODE – Body mass index, airway Obstruction, Dyspnea, Exercise index. MMRC – Modified 
Medical Research Council. SGRQ – St. George’s Respiratory Questionnaire. CCQ – Clinical COPD 
Questionnaire. Tregs – regulatory T lymphocytes. 6MWT – 6-minute walking test. 
 
Table 6: Summary of phase I clinical trials for MSC therapy in COPD. 
 
 
One very recent study in 2020 examined the use of human umbilical cord derived 
MSC therapy in patients with COVID-19, and while long-term results of this study have 
not been reported, it was found that the treatment is thus far well-tolerated.61 Another 2018 
study demonstrated feasibility, safety, and tolerance of MSC therapy in chronic lung 
allograft dysfunction.62 Additionally, phase II clinical trials of MSC therapy in acute 
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respiratory distress syndrome (ARDS) are now under way.63 Phase I clinical trials of MSC 
therapy in COPD patients will undoubtedly continue, as will studies of MSC treatment for 
a variety of other diseases that have overlapping components with COPD such as the two 
above, altogether expanding our understanding of this novel therapeutic option. 
 
Modified MSCs 
It has been discovered that COPD patients have an increased MSC fraction in the 
lungs, as well as an increased subset of CD90+ CD146+ MSCs.64 Soluble CD146, a factor 
understood to promote vascular repair, is also found to increase in plasma and 
bronchoalveolar fluid (BALF) in smokers with COPD.65 However, the vascular support 
function of the CD90+ CD146+ MSCs appears to disappear with COPD, as they appear to 
sense excessive stiffness in the ECM and enter into a upregulated fibrinolytic state.64 While 
this information suggests the importance of studying the precise subset of MSCs which 
will be most valuable in treating COPD, it also highlights limitations of simply providing 
a greater number of cells which may be equally incapable of combatting disease 
progression as those already existing in the lungs. One avenue to circumvent issues such 
as this would be to modify cells ex vivo prior to transplantation. 
In 2014, rats LPS and CS-induced emphysema were infused with MSCs, and one 
group received vector transfected MSCs. This was an rAAV-SPA-TK vector transfection, 
designed to increase MSC grafting. It succeeded at causing the engraftment of a greater 
number of cells, but a noticeable side effect was the induction of fibrosis. HIF-1𝛼 and SDF-
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1 expression, together involved in angiogenesis and promotion of oxygen delivery to 
hypoxic regions, were both increased in the transfection group.66 
 A 2018 study of mice with elastase-induced emphysema utilized MSC infusion, 
ATRA administration, and a combined treatment of both MSCs and ATRA. The study 
found that while both treatments function independently to increase static lung compliance, 
decrease MLI, and decrease alveolar surface area, they also work synergistically to produce 
better results together. The study honed in on mechanisms by which each therapy delivers 
its results, and found that MSCs with the kinase p70S6k1 knocked out did not deliver the 
same level of benefit in the endpoints analyzed, and an upregulation of this gene increased 
that benefit.67 
 A 2019 study of mice with elastase or CS-induced emphysema administered WJ-
MSCs intravenously as a treatment. However, prior to administration, the MSCs for one 
group of mice was pretreated with pioglitazone. Pioglitazone is a drug typically used to 
control high blood sugar in type 2 diabetes, and in this study, the pretreatment resulted in 
increased production of multiple growth factors by MSCs and an improvement, albeit 
insignificant, in MLI on lung histology.68 
In 2019, another group pre-differentiated AF-MSCs into lung epithelial progenitor-
like cells (LEPLCs). These cells were administered intratracheally to mice with elastase-
induced emphysema, and they showed improved benefit over undifferentiated AF-MSCs. 
In mice receiving pre-differentiated AF-MSCs, airway inflammation was further 
ameliorated, growth factors such as VEGF were further increased, MMPs and lung 
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remodeling factors were further reduced, fewer TUNEL+ apoptotic cells were seen, MLI 
was further reduced, and less collagen deposition was observed.69 
 
Conditioned Media and Extracellular Vesicles 
 With MSC therapy proven efficacious in treating multiple different diseases, 
traditional cell transplantation was a logical primary aim in the investigation of a role for 
MSCs in COPD treatment. However, recent research has exposed a deeper understanding 
of MSC anti-inflammatory mechanisms. The recognition that MSC-mediated benefits 
appear to be largely due to paracrine signaling has pushed the field to consider alternative 
methods of use for MSCs. Two methods of applying MSCs as therapy without 
transplantation of actual cells involve the use of MSC conditioned media (MSC-CM) and 
MSC-derived extracellular vesicles (MSC-EVs). 
As has been demonstrated by many studies already referenced, MSCs impart much 
of their influence extracellularly through different signaling mechanisms. The secreted 
products which act on behalf of MSCs are collectively referred to as the secretome, and 
these include cytokines, chemokines, growth factors, angiogenic factors, and extracellular 
vesicles (EVs). EVs secreted by MSCs facilitate the transfer of bioactive factors and can 
modulate function of surrounding cells through ligan-receptor interactions, membrane 
fusion, endocytosis, and phagocytosis. The full secretome can be captured in MSC 
conditioned media (CM), and EVs can in turn be isolated from that CM.29 
 A 2011 study compared the use of MSCs and MSC-CM. The CM was prepared by 
incubating MSCs in serum-free DMEM for 24 hours, then filtered and concentrated 20-
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fold. In vitro, MSC-CM significantly induced proliferation of human pulmonary artery 
endothelial cells (HPAECs), while conditioned media of multiple other cell types did not. 
Next, rats with CS-induced emphysema were either given a single retrobulbar injection of 
6×105 MSCs or 10 biweekly intravenous CM infusions. MSCs and CM demonstrated an 
equal ability to restore alveolar architecture, both significantly reducing MLI to near 
control levels. Both treatments also significantly increased the number of small vessels. 
Both treatments also suppressed right ventricular systolic pressure (RVSP) elevation, but 
this change was insignificant only in the CM group.40 
 A 2019 study compared therapeutic effects of MSCs and MSC-EVs in mice with 
CS-induced COPD. Mouse MSCs were used for the study, and EVs were isolated from 
mouse MSC-CM. Following COPD induction, mice received vehicle control, MSCs, EVs 
or combined MSCs and EVs via intraperitoneal injection. All three treatment groups saw 
a decrease in the number of inflammatory cells in BAL. However, decreases in 
inflammatory cytokine levels and matrix remodeling factors as well as an upregulation in 
mitochondrial transfer-related genes were only seen in the combined MSC and EV 
treatment group. These results suggest an added benefit of EV treatment with MSC therapy 
in combatting inflammation and oxidative stress.70 
A 2021 study examined hUC-MSCs, MSC-CM, and MSC-EVs each in treatment 
of rats with CS-induced COPD. Each of the three treatments or vehicle control were 
administered intratracheally, and all three treatments showed similar effects in reducing 
peribronchial and perivascular inflammation, reducing immune cell infiltration, and 
decreasing nuclear p65, a pro-inflammation indicator. The number of mucous-secreting 
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goblet cells was also reduced in all three treatment groups. MLI decreased in all treatment 
groups, but notably this change was only significant in the EV group. This study further 
indicates similar capabilities of both EVs and CM to those previously shown by MSCs.71 
Finally, a group in 2020 developed an MSC derived product called “Exosome-
derived multiple allogenic protein paracrine signaling (Exo-d-MAPPS).” Isolated from 
placenta-derived MSCs (PL-MSCs), Exo-d-MAPPS contains a high concentration of 
multiple immunosuppressive factors, which include TNF receptors I and II, IL-1 receptor 
antagonist, and soluble receptor for advanced glycation end products (sRAGE). The group 
administered Exo-d-MAPPS via intraperitoneal injection into CS-induced COPD mice and 
found a number of benefits against controls. The treatment improved respiratory function, 
Attenuated chronic airway inflammation, downregulated inflammatory cytokines (TNF-
alpha, IL-1beta, IL-12, IFN-gamma), and increased the immunosuppressive cytokine IL-
10. This was accomplished by attenuating inflammatory cytokine production in lung-
infiltrated immune cells, alleviating antigen-presenting properties of certain immune cells, 
and activating alternative immunosuppressive cells.72 
The Exo-d-MAPPS treatment has already been brought into clinical trials by this 
group. In 30 COPD patients, the solution was inhaled once weekly for three weeks and 
tolerated well by all. No adverse effects related to Exo-d-MAPPS administration were 
documented, and all 30 patients were noted to have improved pulmonary status. Patients 
saw and increase in percentage change of FEV1, improved CCQ score, and increased 6-
minute walking distance. Emphysematous changes were significantly alleviated after one 
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month on CT scans, as evidenced by less lung hyper expansion, less flattened diaphragms, 
and reduced paraseptal and centrilobular emphysema.72  
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DISCUSSION AND CONCLUSION 
 
 Research surrounding the use of MSC therapy in treatment of COPD has turned in 
very promising results to this point. Rodent models of emphysema have revealed a capacity 
of transplanted MSCs to significantly ameliorate alveolar damage, limiting apoptosis and 
returning alveolar architecture nearer to a healthy appearance. Transplanted MSCs 
additionally showed an ability to engraft in alveolar tissue and differentiate into type II 
alveolar cells.45 Moreover, rodent COPD models elucidated clear immunomodulatory 
capacities of transplanted MSCs. Both intravenous and intratracheal administration of 
MSCs have resulted in downregulation of inflammatory cytokines, upregulation of anti-
inflammatory cytokines, diminished inflammatory and immune cell infiltration of lung, 
and relief of oxidative stress.50 51 52 
 While animal models are inherently flawed, early clinical trials of MSC therapy in 
COPD patients have replicated some positive findings. First and foremost, as has been the 
case in studies of MSC therapy in other diseases, transplantation of MSCs in COPD 
patients has to this point been safe, tolerable, and feasible, without exception. This has been 
the case in patients with mild to very severe COPD, including those with severe 
emphysema. In all published phase I clinical trials, exactly zero MSC administration-
related toxicities, adverse events, or deaths have been reported.27 58 55 56 59 60 54 This finding 
is certainly significant, as it is in human studies of any tissue transplantation. 
 Clinical studies have additionally reported preliminary evidence of a number of 
different benefits of MSC therapy to this point. In patients with emphysema, tissue 
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regenerative capacities have been displayed in which microvasculature responds in the 
most damaged areas of the lung.58 Immunomodulatory capabilities of transplanted MSCs 
have been displayed, as evidenced by downregulation of inflammatory cytokines, 
upregulation of anti-inflammatory cytokines, diminished inflammatory and immune cell 
infiltration of lung, and relief of oxidative stress.59 Furthermore, patients who received 
MSC transplantations have seen an improvement in quality of life indicators and breathing 
and exercise capacities.55 56 60 
 Mechanisms through which MSCs impart the demonstrated benefits continue to be 
uncovered, and progressed understanding will provide further guidance in deciding how to 
tailor MSC therapy for COPD patients. More studies are required to increase the power of 
observed results. The clinical studies reviewed in this manuscript had a median enrollment 
of only 10 patients, with a maximum of 62. In addition to larger patient enrollment, a longer 
period of observation and data collection will be necessary, on the magnitude of years. 
MSC therapy has been designed to target the persistent nature of chronic airway 
inflammation in COPD, and thus it is critical to understand not just the magnitude of short-
term relief but also the duration of its effect. Additionally, an expansion of efficacy-related 
study endpoints will be useful. If possible, an approximation of goblet cell number and 
airway mucous secretion density and quantity would help elucidate if MSC therapy is 
capable of ameliorating goblet cell hyperplasia and mucous hypersecretion. Goblet cell 
hyperplasia is not easily quantified unless through airway biopsy, but if certain secreted 
factors can be used as a correlate for hyperplasia, or if mucous secretion can be quantified 
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either physically or radiologically, this would be an important advancement in study 
endpoints. 
 There remain a number of questions yet to be adequately addressed regarding the 
ideal method of MSC therapy in COPD. Cell source is one area with copious room for 
clarification. MSCs are readily isolated from multiple different tissue sources. A majority 
of both pre-clinical and clinical studies isolated MSCs from bone marrow. Additional 
studies have used a number of other sources, including adipose tissue, lung tissue, 
umbilical cord, amniotic fluid, placenta, and through differentiation of induced-pluripotent 
stem cells (iPSCs). No studies have yet adequately confronted the question of differences 
in efficacy between MSCs derived from different sources. Research has highlighted the 
existence of multiple MSC subdivisions, but has not clearly elucidated which cells are most 
appropriate for a given therapeutic purpose.64 
 When autologous MSC transplant is the chosen method, BM-MSCs make logical 
sense; they are easily isolated and expanded for use in a different tissue. However, an 
important question for researchers to consider is whether autologous transplantation is the 
most effective means of MSC therapy. Multiple studies have noted a deleterious impact of 
CS-exposure and COPD on a patient’s own stem cell populations. This impact stretches to 
MSCs, including both LR-MSCs and BM-MSCs. One study identified a reduction in LR-
MSC capacity to reduce T cell proliferation in current smoker COPD patients.37 Reported 
reductions in proliferation, migration, and engraftment capacities of BM-MSCs in COPD 
garner consideration of how trophic signaling, immunomodulatory, and tissue regenerative 
capacities of these cells are impacted relative to BM-MSCs in a non-COPD individual.34 
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35 36 A significant draw of MSCs as an agent of therapy is their reportedly low 
immunogenicity.27 As such, if BM-MSCs in COPD patients are in fact damaged, a matched 
allogenic transplant would be a worthy consideration. 
 Delivery route is another important component of MSC transplantation which must 
be further studied. A majority of clinical trials have opted for systemic administration via 
intravenous infusion. The alternative options, which have been used sparingly in clinical 
trials to this point, are intratracheal infusion or inhalation using a nebulizer. Adequate 
comparisons do not yet exist to determine which approach projects more effective, however 
pre-clinical and clinical studies have found beneficial effects using both methods. 
 One final unanswered question is in regard to the target population for this therapy. 
Beneficial effects of MSC transplantation, as described earlier, have been reported in a 
range of COPD patients from mild to very severe and including those with advanced 
emphysema. It is unlikely that any given therapy would benefit all COPD patients equally, 
as it is a multi-faceted disease with multiple possible pathological components. It is 
possible that research will reveal a heightened benefit of MSC therapy for some patients 
but not others over the current GOLD-recommended regimens of treatment. 
 New approaches to MSC therapy warrant strong consideration. Certain studies have 
begun examining methods to modify MSCs. These modifications include vector 
transfection to improve engraftment, upregulation of specific kinases, and pre-
differentiation into lung epithelial progenitor-like cells (LEPLCs). These modifications 
have resulted in both anticipated and unanticipated positive and negative changes in cell 
behavior.66 67 69 These studies highlight the reality that there are a conceivably indefinite 
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number of ways to modify MSCs to influence cell behavior. Choosing the correct alteration 
or combination of alterations may prove elusive in the short-term, and based on early 
clinical trials of unmodified MSC therapy there does not appear a need to pivot rapidly to 
any specific modification. However, cellular modifications, whether genomic or involving 
pre-differentiation or pre-treatment, do offer an important avenue to build research towards 
the optimal treatment, if one does exist involving the use of MSCs, and should be pursued. 
 There has also been a recent rise in research around the use of MSCs in a more 
indirect manner of therapy for COPD. Conditioned media and extracellular vesicles have 
been a focus by some in recent years, and given the importance of MSC paracrine signaling 
in cell therapy, it is understood that these substances could contain a high enough 
concentration of critical signaling molecules to impart the same beneficial effects as a dose 
of MSCs. Specifically, the MSC-CM derived product termed “Exo-d-MAPPS” contains a 
number of the most critical anti-inflammatory agents responsible for MSC 
immunomodulatory functions, and showed great promise both in a pre-clinical and clinical 
study at alleviating emphysema, reducing airway inflammation, and improving pulmonary 
function.72 Other MSC-derived products (CM and EVs) have demonstrated similar levels 
of improvement in lung pathology and function to MSC transplantation when compared 
directly.40 70 71 While a greater amount of research into MSC-CM and MSC-EV therapeutic 
capacity is needed, including more direct comparisons with MSC transplantation, it is also 
worth considering the functionality and financial component of a treatment such as this 
compared to one which requires transplantation of live cells on multiple occasions. 
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Moreover, if certain patient populations have not warmed to the somewhat foreign concept 
of stem cell transplantation, this might be a method more individuals are likely to embrace. 
 Finally, it is important that all considerations of MSC therapy be made with regard 
to currently approved treatments and others undergoing testing. MSC therapy does offer a 
potential way to combat the chronic nature of airway inflammation such that no other 
treatment effectively has to this point. Should these benefits be proven powerful and 
enduring enough to suppress inflammation and delay, halt, or even reverse disease 
progression and lung destruction, MSC therapy may very well become a critical component 
of integrated care for COPD. Lifestyle changes will remain an important aspect of 
integrated care, as they improve the odds of any other treatment succeeding.3 Currently 
approved pharmacologic agents such as bronchodilators will likely not be entirely replaced, 
as they are may in some instances provide needed relief of some irritating and sometimes 
debilitating disease components such as dyspnea and frequency of exacerbation.13 
 The area of COPD treatment in need of the greatest improvement is in combatting 
inflammation. Inhaled corticosteroids (ICS) remain a component of GOLD-recommended 
treatment regimens, but their efficacy is known to be limited due to COPD-induced steroid 
resistance.15 The true test of MSC therapy in COPD will be its observed benefits in 
comparison with other non-steroidal anti-inflammatory drugs (NSAIDs). Multiple 
different targeted NSAIDs are currently being studied as mechanisms to circumvent steroid 
resistance and suppress chronic inflammation in the lungs.  
 PDE4 inhibitors have demonstrated anti-inflammatory capacities in COPD 
patients, resulting in improved lung function and reduced exacerbations in advanced 
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COPD.16 17 MAPK inhibitors have improved lung function and dyspnea.73 And hope 
remains for positive results from clinical studies of targeted cytokine and chemokine 
inhibitors.16 There is no reason that MSC therapy and NSAIDs cannot coexist as treatment 
options if each proven efficacious. However, NSAIDs are more targeted agents of therapy, 
each designed to be effective against certain pathways in the inflammatory response. MSC 
research, from in vitro studies to phase I clinical trials, has shed light on the capacity of 
MSCs to modulate the inflammatory response through a range of different pathways, 
expanding the potential for wide-scale inflammation suppression. 
To this point, despite the theoretical edge of MSCs, evidence cannot clearly 
elucidate if either MSC therapy or a specific NSAID treatment imparts greater anti-
inflammatory benefits on COPD patients. However, the demonstrated capacity of 
transplanted MSCs to augment the tissue regeneration process, particularly in distal lung 
tissue in models of emphysema, is a component of therapeutic efficacy that NSAIDs are 
not designed for or capable of. A therapy of this variety has the potential to provide 
heightened levels of relief and disease reversal. One other treatment which showed promise 
pre-clinically in emphysema amelioration was the retinoid ATRA, which sadly fell flat in 
clinical trials. (20, 21) Whether MSCs eventually do demonstrate emphysema amelioration 
in humans as significant and enduring as that seen in animal testing, the combined anti-
inflammatory and tissue regenerative potential of MSC therapy looms large in the 
landscape of COPD treatments. 
Studies will continue to seek elucidation of the optimal approach towards MSC use. 
With proper resources allocated to adequately answering questions regarding cell source, 
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cell number, delivery route, and use of cellular modifications or MSC-derived products, 
researchers will determine the extent of optimal MSC therapy efficacy in COPD. Reported 
results in the coming years with dictate if MSC therapy becomes a de facto component of 
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